Tune Therapeutics
PrivateLast Round
Series B
Jan 12, 2025
Est. Valuation
$339.8M
Total Funding Raised
$223.35M
Company Overview
Tune Therapeutics is a biotechnology company that develops an epigenetic programming platform aimed at creating innovative cell and gene therapies for the treatment of complex diseases by reprogramming biology through the epigenome without modifying the DNA sequence.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tune Therapeutics Comparables
Compare Tune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Moonwalk Biosciences | 89% | |
| Epicrispr Biotechnologies | 88% | |
| Epigenic Therapeutics | 88% |
Tune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 12, 2025 | ||||
| Series A | Dec 2, 2021 |
Key People
Founding team and executive leadership
Tune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| A. M. Pappas & Associates | Series B |
| New Enterprise Associates | Series A, Series B |
| Duke Capital Partners | Series A, Series B |
| WRF Capital | Series B |
| Hatteras Venture Partners | Series A |
| Hevolution Foundation | Series B |
| Yosemite | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2025
Dr. John McHutchison appointed as new Chief Executive Officer.
- Jan 22, 2025
Attended and showcased advancements at the JPM 2025 conference.
Recent news
Latest coverage and updates
- is_developingOct 6, 2026
Tune Therapeutics, Inc. is developing TUNE-401 as a potential treatment for chronic hepatitis B
- recognized_asOct 6, 2026
Tune Therapeutics, Inc. earns recognition in Fierce Biotech's 2026 Fierce 15
Tune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Tune Therapeutics's valuation, stock price, and market status.
Is Tune Therapeutics a public or private company?
Tune Therapeutics is a private company.
What is the current stock price of Tune Therapeutics?
Tune Therapeutics is a private company, so its shares have no public market price. Caplight tracks Tune Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tune Therapeutics worth (valuation)?
Tune Therapeutics's valuation is estimated at $339.8M based on funding round data.
Can I buy Tune Therapeutics stock?
Tune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tune Therapeutics's last funding round?
Tune Therapeutics's most recent funding round was Series B on January 12, 2025.
Who are the main investors in Tune Therapeutics?
Key investors in Tune Therapeutics include New Enterprise Associates, Hevolution Foundation, Yosemite, Emerson Collective.
Will Tune Therapeutics IPO soon?
No public IPO plans have been announced for Tune Therapeutics.
How can I track Tune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Tune Therapeutics's shares on secondary markets.